Ocugen To Enter License Agreement With Roots Pharmaceutical For Rights To OCU400, Its Novel Modifier Gene Therapy For Retinitis Pigmentosa, In The Middle East And North Africa
Benzinga Newsdesk 3 months ago
ContractsNews
Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400
- Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones
- Royalties equaling 22% of net sales
- Ocugen to manufacture and supply OCU400